Long-term results of st jude total therapy studies 11, 12, 13a, 13b, and 14 for childhood acute lymphoblastic leukemia

Leukemia

Volumn 24, Issue 2, 2010, Pages 371-382

  Pui, C H ^a,b   Pei, D ^a   Sandlund, J T ^a,b   Ribeiro, R C ^a,b   Rubnitz, J E ^a,b   Raimondi, S C ^a,b   Onciu, M ^a,b   Campana, D ^a,b   Kun, L E ^a,b   Jeha, S ^a,b   Cheng, C ^a   Howard, S C ^a,b   Metzger, M L ^a,b   Bhojwani, D ^a,b   Downing, J R ^a,b   Evans, W E ^a,b   Relling, M V ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

B lineage ALL; Chemotherapy; CNS relapse; Leukemia; Prognostic factors; T lineage ALL

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BASAL CELL CARCINOMA; BRAIN TUMOR; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DNA DETERMINATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; EWING SARCOMA; FEMALE; GENETIC POLYMORPHISM; HUMAN; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENETICS; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; TREATMENT RESPONSE;

EID: 76749138468     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.252     Document Type: Article

References (56)

1. Rivera G, Pinkel D, Simone JV, Hancock ML, Crist WM. Treatment of acute lymphoblastic leukemia. 30 years' experience at St Jude Children's Research Hospital. N Engl N Med 1993; 329: 1289-1295.
2. Pui CH, Simone JV, Hancock ML, Evans WE, Williams DL, Bowman WP et al. Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: long-term results of St Jude Total Therapy Study X. Leukemia 1992; 6: 150-157.
3. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui CH, Abromowitch M et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337: 61-66.
4. Pui CH, Behm FG, Raimondi SC, Dodge RK, George SL, Rivera GK et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 1989; 321: 136-142.
5. Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325: 1682-1687.
6. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998; 338: 499-505.
7. Pui CH, Mahmoud HH, Rivera GK, Hancock ML, Sandlund JT, Behm FG et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 1998; 92: 411-415.
8. Barredo JC, Synold TW, Laver J, Relling MV, Pui CH, Priest DG et al. Differences in constitutive and post-methotrexate folypoly-glutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 1994; 84: 564-569.
9. Synold TW, Relling MV, Boyett JM, Rivera GK, Sandlund JT, Mahmoud H et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 1994; 94: 1996-2001.
10. Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT et al. Accumulation of methotrexate polyglutamates in lympho-blasts is a determinant of antileukemic effects in vivo: a rationale for high-dose methotrexate. J Clin Invest 1996; 97: 73-80.
11. Galpin AJ, Schuetz JD, Masson E, Yanishevski Y, Synold TW, Barredo JC et al. Differences in folypolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol 1997; 52: 155-163.
12. Belkov VM, Krynetski EY, Schuetz JD, Yanishevski Y, Masson E, Mathew S et al. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood 1999; 93: 1643-1650.
13. Pui CH, Boyett JM, Rivera GK, Hancock ML, Sandlund JT, Ribeiro RC et al. Long-term results of total therapy studies 11, 12, and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000; 14: 2286-2294.
14. Pui CH, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC et al. Improved outcome for children with acute lymphoblastic leukemia: results of total therapy study XIIIB at St Jude Children's Research Hospital. Blood 2004; 104: 2690-2696.
15. Kishi S, Griener J, Cheng C, Das S, Cook EH, Pei D et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003; 21: 3084-3091.
16. Pui CH, Relling MV, Sandlund JT, Downing JR, Campana D, Evans WE. Total Therapy study XV for newly diagnosed childhood acute lymphoblastic leukemia: study design and preliminary results. Ann Hematol 2006; 85 (Suppl 1): 88-91.
17. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC et al. Treating childhood acute lymphoblastic leukemia without prophylactic cranial irradiation. N Engl J Med 2009; 360: 2730-2741.
18. Kishi S, Cheng C, French D, Pei D, Das S, Cook EH et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007; 109: 4151-4157.
19. Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH et al. Pharmacogenetics of outcome in children with acute lympho-blastic leukemia. Blood 2005; 105: 4752-4758.
20. Relling MV, Pui CH, Cheng C, Evans WE. Thiopurine methyl-transferase in acute lymphoblastic leukemia. Blood 2006; 107: 843-844.
21. Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999; 354: 34-39.
22. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91: 2001-2008.
23. Relling MV, Yanishevski Y, Nemec J, Evans WE, Boyett JM, Behm FG et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998; 12: 346-352.
24. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1996; 50: 163-170.
25. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Wiley: New York, NY, 2002.
26. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1998; 16: 1141-1154.
27. Pui CH, Cheng C, Leung W, Rai SN, Rivera GK, Sandlund JT et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Eng J Med 2003; 349: 640-649.
28. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 18-24. (Pubitemid 26019992)
29. Mahmoud HH, Rivera GK, Hancock ML, Krance RA, Kun LE, Behm FG et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med 1993; 329: 314-319.
30. Gajjar A, Harrison PL, Sandlund JT, Rivera GK, Ribeiro RC, Rubnitz JE et al. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood 2000; 96: 3381-3384.
31. Bürger B, Zimmermann M, Mann G, Kühl J, Löning L, Riehm H et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 2003; 21: 184-188.
32. Hijiya N, Hudson M, Lensing S, Zacher M, Onciu M, Behm FG et al. Cumulative incidence of secondary neoplasms as a first event after treatment of childhood acute lymphoblastic leukemia. JAMA 2007; 297: 1207-1215. (Pubitemid 46465729)
33. Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 2008; 9: 257-268.
34. Jeha S, Pei D, Raimondi SC, Onciu M, Campana D, Cheng C et al. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia 2009; 23: 1406-1409.
35. Pui CH, Relling MV, Rivera GK, Hancock ML, Raimondi SC, Heslop HE et al. Epipodophyllotoxin-related acute myeloid leukemiaFa study of 35 cases. Leukemia 1995; 9: 1990-1996.
36. Pui CH, Relling MV, Behm FG, Hancock ML, Boyett JM, Raimondi SC et al. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 1995; 9: 1680-1684.
37. Relling MV, Boyett JM, Blanco JG, Raimondi S, Behm FG, Sandlund JT et al. Granulocyte colony stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003; 101: 3862-3867.
38. Schmiegelow K, Forestier E, Kristinsson J, Söderhäll S, Vettenranta K, Weinshilboum R et al. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia 2009; 23: 557-564.
39. Pui CH, Evans WE. Treatment for acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178.
40. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030-1043.
41. Pui CH, Sandlund JT, Pei D, Rivera GK, Howard SC, Ribeiro RC et al. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 2003; 290: 2001-2007.
42. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukemia. Lancet 1998; 351: 550-554.
43. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 2691-2696.
44. Coustan-Smith E, Sancho J, Behm FG, Hancock ML, Razzouk BI, Ribeiro RC et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002; 100: 52-58.
45. Coustan-Smith E, Ribeiro RC, Stow P, Zhou Y, Pui CH, Rivera GK et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood 2006; 108: 97-102.
46. Fronkova E, Mejstrikova E, Avigad S, Chik KW, Castillo L, Manor S et al. Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia 2008; 22: 989-997.
47. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S et al., International BFM Study Group (I-BFM-SG). Minimal residual disease-directed risk stratification using realtime quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771-782.
48. Ratei R, Basso G, Dworzak M, Gaipa G, Veltroni M, Rhein P et al. Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction. Leukemia 2009; 23: 528-534.
49. Van der Velden VHJ, Corral L, Valsecchi MG, Jansen MWJC, De Lorenzo P, Cazzaniga G et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009; 23: 1073-1079.
50. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D et al. Early T-cell precursor leukaemia; a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10: 147-156.
51. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470-480.
52. den Boer ML, van Slegtenhorst M, de Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009; 10: 125-134.
53. Yang JJ, Bhojwani D, Yang W, Cai X, Stocco G, Crews K et al. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 2008; 112: 4178-4183.
54. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukaemia. N Engl J Med 2004; 350: 1535-1548.
55. Pui CH, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukemia. Nat Rev Drug Discov 2007; 6: 149-165. (Pubitemid 46758753)
56. Yang J, Cheng C, Yang W, Pei D, Cao X, Fan Y et al. Genome-wide interrogation of germline genetic variations associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009; 301: 393-403.